Format

Send to

Choose Destination
Alzheimers Dement. 2018 Jan;14(1):62-70. doi: 10.1016/j.jalz.2017.06.2264. Epub 2017 Jul 12.

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Author information

1
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.
2
Neurochemistry Laboratory, Department of Clinical Chemistry, VU Medical Center, Amsterdam, The Netherlands.
3
Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
4
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands.
5
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
6
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: fagana@wustl.edu.

Erratum in

Abstract

INTRODUCTION:

The best-established cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease are levels of amyloid β 42 (Aβ42), total tau (tau), and phosphorylated tau 181 (ptau). We examined whether a widely used commercial immunoassay for CSF Aβ42, tau, and ptau provided stable measurements for more than ∼10 years.

METHODS:

INNOTEST assay values for CSF Aβ42, tau, and ptau from Washington University in St. Louis and VU Medical Center, Amsterdam, were evaluated.

RESULTS:

Aβ42 values as measured by the INNOTEST assay drifted upward by approximately 3% per year over the past decade. Tau values remained relatively stable, whereas results for ptau were mixed.

DISCUSSION:

Assay drift may reduce statistical power or even confound analyses. The drift in INNOTEST Aβ42 values may reduce diagnostic accuracy for Alzheimer's disease in the clinic. We recommend methods to account for assay drift in existing data sets and to reduce assay drift in future studies.

KEYWORDS:

Alzheimer disease; Amyloid; Assay drift; Biomarker; Cerebrospinal fluid; Cutoff; INNOTEST; Quality control

PMID:
28710906
PMCID:
PMC5750131
DOI:
10.1016/j.jalz.2017.06.2264
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center